Biotech Thursday: First Patient Dosed, 107-Month Runways, $534K Insider Adds
Top 5 Pixie Picks
This Week's Setup
Clinical density is the signal this week: nine Phase 3 programs at IDEAYA, eleven at Ionis, and twenty-two at Incyte, while Viking runs dual Phase 3 obesity studies and Revolution Medicines keeps RAS programs in front of patients.
IDEAYA just enrolled its first IDE574 patient, Ionis has Zilganersen under FDA priority review in ATTR, and Zymeworks shows $534K of insider adds on an ADC platform with 55% upside to targets. The screen rewards runways, dosing events, and insider tickets more than sector beta.
The nine active trials span metastatic uveal melanoma and colorectal cancer, with two programs already in Phase 3 and four in Phase 2. The 107-month cash runway supports a multi-year pipeline buildout at a current ratio of 11.34; dilution over the past year was 1.49%, among the lowest in the cohort.
⬡ IDEAYA enrolled the first patient in a Phase 1 trial of IDE574, a dual KAT6/7 inhibitor targeting breast, prostate, CRC, and lung cancer. The drug addresses epigenetic mechanisms in tumor proliferation; preclinical data showed activity in KRAS-driven models, a market segment Revolution Medicines and Mirati are both targeting with different mechanisms.
Short interest sits at 11.2% of the float. The stock is down 16.7% from its 52-week high despite the Phase 1 start; the market is pricing in trial execution risk and the two-to-three-year timeline before Phase 2 data.
⬡ Zilganersen, an antisense drug targeting transthyretin, is under FDA priority review. If approved, it joins a crowded but high-value ATTR market alongside Pfizer's Vyndaqel and Alnylam's Onpattro; Ionis's mechanism targets production at the RNA level, potentially offering dosing advantages over small molecules and RNAi competitors.
Insider Shannon Devers sold $1,686,302 worth of shares on April 2, 2026. Patrick O'Neil and Eugene Schneider also transacted in March, but the net position over six months is -31,324 shares. The sales follow a 13.8% drawdown; insiders are lightening exposure into strength rather than adding during weakness.
Two Phase 3 trials are evaluating VK2735 for obesity, positioning Viking in the GLP-1 agonist market alongside Novo Nordisk and Eli Lilly. The 166% analyst upside target reflects expectations of strong efficacy data and a potential partnership or acquisition; the stock is down 19.4% from peak despite no trial setbacks.
Insider Neil William Aubuchon acquired shares on March 10, 2026; net insider activity over the past six months is +177,031 shares, with insiders buying 21.3% of the time and selling 15.5%. The adds coincide with the drawdown, suggesting management confidence in the Phase 3 timeline.
Short interest is 21.6% of the float, the highest in the top eight. Bears are betting on competitive pressure from Lilly's oral Foundayo and on the risk that VK2735 data underperform relative to the $92.72 consensus price target.
Rezdiffra, a commercial-stage treatment for NASH, drove 432% year-over-year revenue growth; gross margin is 94.1%. The 62-month cash runway and 4.01 current ratio support continued commercial expansion without near-term dilution pressure.
⬡ Three Phase 3 trials are active, targeting MASH, cirrhosis, and broader liver disease indications. The programs extend Rezdiffra's label into higher-risk patient populations; positive data would expand addressable market size and justify the $668 analyst target.
Short interest is 31.5% of the float, the highest in the top eight. Bears are pricing in reimbursement headwinds and competition from Novo Nordisk's semaglutide, which has shown liver benefit in obesity trials and may encroach on the NASH franchise.
⬡ Revolution initiated patient dosing in RASolute 303, a Phase 3 trial evaluating daraxonrasib as first-line treatment for metastatic pancreatic cancer. The program addresses KRAS G12D mutations, a target with limited therapeutic options; the stock is down 20.4% despite the trial start, reflecting the long path to approval and high failure rates in pancreatic cancer trials.
Four Phase 3 programs are active, targeting non-small cell lung cancer and colorectal cancer with RAS inhibitors RMC-6291 and elironrasib. The pipeline is the broadest in the precision oncology segment; all 18 analysts covering the stock rate it a buy or strong buy.
Insiders Xiaolin Wang, Stephen Michael Kelsey, and Jack Anders all acquired shares on March 19, 2026. Net insider activity over six months is +227,272 shares, the second-highest dollar commitment in the top eight after Zymeworks.
Incyte is profitable with a 14.97 P/E, 7.0% FCF yield, and 133 active trials spanning myelofibrosis, polycythemia vera, and pancreatic cancer. Twenty-two Phase 3 programs are running; revenue grew 21.2% year-over-year, and gross margin is 92.8%.
Edmund Harrigan and Paul Clancy both transacted on April 2, 2026; Matteo Trotta sold on March 26. Net insider activity over six months is -280,177 shares, with insiders selling 8.9% of the time and buying 1.9%. The selling follows a 14.6% drawdown; insiders are taking profits rather than adding exposure.
Analyst net bullish sentiment is 44.0%, the lowest in the top eight. The market is pricing in patent expiration risk on Jakafi, which generated $2.3 billion in 2024 sales and faces biosimilar competition starting in 2028.
The antibody-drug conjugate platform is advancing ZW49 in Phase 3 for HER2-expressing cancers and ZW171 in Phase 2 for solid tumors. Revenue grew 38.9% year-over-year; the 83-month cash runway supports multi-trial execution without near-term financing risk.
CFO Kristin Stafford acquired shares on April 7, 2026, the most recent insider transaction in the cohort. Net insider activity over six months is +201,026 shares, with insiders buying 53.4% of the time and selling 25.8%; the $534K net commitment is the highest dollar value in the top eight.
Dilution over the past year was 9.03%, the highest in the top eight. The stock is up 0.38% over the trailing twelve months despite the insider adds; the market is discounting the pipeline for execution risk and the crowded ADC competitive landscape.
DAYBUE STIX, a formulation of trofinetide for Rett syndrome, is now broadly available in the U.S. The product addresses a rare pediatric neurological disorder with no other approved treatments; uptake will determine whether the label expansion justifies the 43.5% analyst upside target.
The stock is down 21.7% from its 52-week high; insiders added 16,983 shares over the past six months, with Mark Schneyer, Elizabeth Thompson, and Catherine Owen all transacting in the period. The adds are modest relative to the drawdown size; insiders are expressing confidence but not conviction.
Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Biotech stocks.
⬡ No tracked biotech securities reported pipeline events in the past seven days. The quiet week follows a high-density March, when Revolution Medicines began dosing in RASolute 303 and IDEAYA enrolled its first patient in the IDE574 Phase 1 trial. The calendar ahead is loaded: eleven Phase 3 programs at Ionis are progressing toward readouts, twenty-two at Incyte are generating data across oncology and inflammatory disease indications, and Viking's two Phase 3 obesity trials will deliver top-line efficacy data in the next twelve months. The near-term risk is binary event density: a single Phase 3 miss at any of the top names would reprice the sector overnight, given the 8–32% short interest across the cohort and the reliance on trial success to justify the 22–166% analyst upside targets. Incyte's 133 active trials and Ionis's eleven Phase 3 programs offer portfolio diversification; IDEAYA, Revolution, and Viking are single-asset concentration bets where trial timelines are the entire investment case.
What to Watch
IDEAYA Phase 1 IDE574 enrollment progress (Q2 2026): The dual KAT6/7 inhibitor is targeting breast, prostate, CRC, and lung cancer; the 107-month cash runway gives management time to dose cohorts methodically, but any safety flags in the first 20 patients would force a protocol amendment and delay the Phase 2 start by six months.
Ionis zilganersen FDA priority review decision (expected Q2 2026): Approval would validate the antisense platform in ATTR cardiomyopathy and add a third commercial-stage asset to the portfolio; rejection or CRL would trigger a 15–20% selloff and force insiders to address the -31,324 net share position over the past six months.
Viking VK2735 Phase 3 top-line data (expected H2 2026): The obesity franchise is the entire investment case; the 21.6% short interest reflects skepticism that efficacy will match Novo's semaglutide or Lilly's tirzepatide. Positive data justifies the 166% analyst target; a miss reprices the stock to $15–$18.
Madrigal Rezdiffra Q2 commercial sales (May 2026 earnings): Revenue grew 432% year-over-year, but the 31.5% short interest reflects reimbursement headwinds; if sales trajectory decelerates below $100M quarterly run-rate, the stock tests $400.
Go Deeper
The biotech screener surfaces pre-revenue and commercial-stage names with multi-year cash runways, insider conviction, and Phase 2/3 catalysts that could reprice valuations in twelve months or less. Check out the full screener →
Free shows up to 10 rows on the biotech screener; Pro and trial see the full ranked list.Start your free trial →
Pro-only analytics
Named tickers from this article open in the app with Pro or an active trial.
See the full biotech screen — every pick, every metric, every day.
The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.
The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.
The Fine Print
Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.